Our interest in 124I was intensified based on the discoveries of Fagin et al. [11], who demonstrated that kinase inhibitors of the MAP-kinase pathway, particularly MEK and BRAF inhibitors, could reinduce RAI tumor uptake in laboratory models of BRAF-mutant thyroid cancer [12]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.